Uterine leiomyoma (UL), also called myoma, is a benign tumor that develops in the smooth muscle of the uterus. It is one of the most common pathologies in women and has been estimated to affect approximately 70% of the premenopausal population. The 30% of women affected by this neoplasm show obvious symptoms and resort to invasive gynecological treatments. The most common symptoms are dysmenorrhea, abnormal bleeding, infertility, recurrent miscarriages, and pelvic pain. Leiomyomas are monoclonal and the synchronous appearance of multiple tumors is common. There are hormonal medical treatments, but to date the most adopted solutions remain surgical ones such as hysterectomy, myomectomy and endometrial ablation which involve irreversible consequences for the patients, including the risk of preterm birth, cesarean section, or infertility(1).